NCT03589222: Phase 2: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

NCT03589222: Phase 2: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

NCT03589222: Phase 2: SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

Phase 2, single-arm, open, non-randomized, multicenter study of the SINE™ compound selinexor plus low-dose dexamethasone, in combination with bortezomib and daratumumab.

Sponsor

PETHEMA Foundation

---

ClinicalTrials.gov Identifier: NCT03589222

Official Title: An Open-label, Multicenter, Phase 2 Trial of Selinexor (KPT-330), Bortezomib and Low-dose Dexamethasone Plus Daratumumab (SELIBORDARA) for the Treatment of Patients With Refractory or Relapsed and Refractory Multiple Myeloma

First Posted : July 17, 2018

Click here for ClinicalTrials.gov

---

Selinexor : National Cancer Institute

Selinexor : MedlinePlus Drug Information

---

Drug: Selinexor

Drug: Daratumumab

Drug: Bortezomib

Drug: Dexamethasone

---

Locations

Europe

Spain